xtant medical holdings inc xtnta company profile  reuterscom x edition united states africa américa latina عربي argentina brasil canada  deutschland españa france india italia  méxico россия united kingdom united states profile xtant medical holdings inc xtnta related topics stocksstock screenerhealthcareadvanced medical equipment  technology overview news key developments people charts financials analysts research pulse xtnta on american stock exchange usd  jul  change  chg   prev close  open  days high  days low  volume  avg vol  wk high  wk low  full description xtant medical holdings inc formerly bacterin international holdings inc incorporated on august   develops manufactures and markets regenerative medicine products and medical devices for domestic and international markets the company operates through the development manufacture and marketing of regenerative medical products and devices segment its biomaterial products include osteosponge osteosponge sc osteoselect dbm putty osteoselect plus dbm putty osteowrap bacfast hd osteostx hmatrix and a range of demin products as well as other allografts the companys products serve the needs of orthopedic and neurological surgeons including orthobiologics for the promotion of bone healing implants and instrumentation for the treatment of spinal disease tissue grafts for the treatment of orthopedic disorders and biologics to promote healing following cranial foot and ankle surgeriesthe company also processes and distributes sports allografts which are processed for anterior and posterior cruciate ligament repairs anterior cruciate ligament reconstruction and meniscal repair milled spinal allografts which consists of cortical bone milled to desired shapes and dimensions and allografts for multidisciplinary applications including orthopedics neurology podiatry oralmaxillofacial genitourinary and plasticreconstructive in the fixation portfolio there are various product families that are used to treat a range of spinal and sacroiliac conditions including trauma degeneration deformity and tumor with a focus on minimally invasive surgery mis its product lines include axle interspinous fusion system silex sacroiliac joint fusion system xpress minimally invasive pedicle screw system certex spinal fixation system butrex anterior lumbar buttress plating system calix spider cervical plating system zyfix facet fusion system fixcet spinal facet screw system fortex pedicle screw system x pedicle screw system irixa lumbar integrated fusion system irixc cervical integrated fusion system axlex interspinous fusion system and xport tissuesparing instrumentation systemthe osteosponge is a form of demineralized bone matrix made from  human bone derived from trabecular cancellous bone osteosponge provides a natural scaffold for cellular ingrowth and exposes boneforming proteins to the healing environment osteosponge are used in various orthopedic practices including spine neurology cranialmaxillofacial trauma plasticreconstruction and general procedures where new bone growth is needed osteosponge sc is a form of osteosponge designed to fill bony defects in the subchondral region of joints osteoselect plus is indicated as a bone void filler and bone graft substitute in the pelvis extremities and posterolateral spine osteowrap has various applications in orthopedic neurological trauma oralmaxillofacial and reconstructive procedures osteowrap can wrap around nonunion fractures to assist with fusion can act as a biologic plate or can be used in conjunction with a hardware plate systemthe bacfast hd facet stabilization dowel is designed with a focus on osteoconductivity and osteoinductive potential bacfast hd provides the graft with osteoinductive properties osteostx are demineralized cortical sticks processed from human allograft bone osteostx are designed for posterolateral spine surgery applications ranging from onelevel to multilevel fusions including scoliosis procedures hmatrix dermal scaffold is an extension of its biologics technology hmatrix is an acellular matrix made from donated human dermal tissue that is used to replace a patients damaged tissue hmatrix provides a natural collagen tissue scaffold that supports cellular ingrowth tissue vascularization and regeneration and reabsorbs into the patients dermal tissue for a biocompatible natural repair demin is a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone its demin products are hydrated with various biocompatible liquid for various bone grafting applications it is used in spinal fusion proceduresthe axle interspinous fusion system is a modular interspinous device that is matched to the patients individual anatomy and is available in multiple implantable configurations the silex sacroiliac joint fusion system is a sacroiliac fixation system which compresses across the sacroiliac si joint the xpress minimally invasive pedicle screw system combines minimally invasive functionality to the lumbar fixation procedurespedicle screw fixation the certex spinal fixation system consists of screws hooks rods and cross connectors various sizes of these implants are available so that adaptations can be made to take into account pathology and individual patient anatomy it is intended to promote fusion of the subaxial cervical spine and cervicothoracic junction ct inclusive the butrex anterior lumbar buttress plating system utilizes the resilient locking arm technology to prevent screw back out the butrex system features an allinone drill guide with a plate retaining feature to allow for better control during plate placement and to protect adjacent structuresthe calix is a family of polyether ether ketone peek interbody spacers and precision instruments for both cervical and thoracolumbar applications calix pc is a frictional titanium plasmacoated peek implants that provide biomechanical performance and endplate visualization the spider cervical plating system consists of single step locking with three forms of locking feedback selfdrilling screws preserve cancellous bone for secure screw purchase the zyfix facet fusion system is a minimally invasive facet fusion system featuring a hollow fenestrated titanium compression screw for bone graft introduction it is intended for bilateral transfacet fixation of the facet joint in order to provide stability for fusion the fixcet spinal facet screw system is a percutaneous facet screw system offering dualcompression thread and singlethread screws it is intended for posterior fixation to the lumbar spine ls inclusive it enables a bilateral transfacet fixation of the facet joint in order to provide stability for fusion the fortex pedicle screw system consists of titanium alloy bone screws rods crossconnectors and associated instruments the system is indicated for attachment to the pedicles of the thoracic lumbar and sacral spine the x pedicle screw system combines rotary locking technology and biomechanical performance allowing for rod locking the pedicle screw system is designed to avoid the problems of cross threading head splay and cap loosening endemic to cap type pedicle screw systemsthe irixa lumbar integrated fusion system consists of an integrated titanium ring surrounded by an outer peek ring and three screws it is intended for spinal fusion procedures at one or two contiguous levels of the lumbosacral spine ls inclusive in skeletally mature patients for the treatment of degenerative disc disease the irixc cervical integrated fusion system consists of an integrated titanium ring surrounded by an outer peek ring and two screws it is intended for spinal fusion procedures at one level ct inclusive in skeletally mature patients for the treatment of degenerative disc disease the axlex interspinous fusion system is an internal fixation device for spinal surgery in the noncervical spine ts inclusive it is a minimally invasive modular interspinous fusion system with angled spikes that allows for adequate ls engagement and other variations in patient anatomy the axlex interspinous fusion system is designed to provide spinal stability for lumbar fusion procedures including the treatment of degenerative disc disease spinal tumors and trauma the xport tissuesparing instrumentation system is designed for surgical access and visualization an ideal partner to the xspine fortex pedicle screw system the radiolucent xport retractor component is integrated with a siderail mounted flexible arm for localization and stability the xport system includes integral tissuesparing instrumentation to allow for compression distraction and rod placementthe company competes with nuvasive rti surgical seaspine medtronic orthofix stryker alphatec zimmer biomet depuysynthes k medical globus medical ldr holding company allosource lifenet health and mtf » full overview of xtnta company address xtant medical holdings inc  cruiser lnbelgrade   mt    p f  company web links home page officers  directors name compensation kent swanson  carl oconnell  john gandolfo  darrel holmes  gregory juda  » more officers  directors xtant medical holdings inc news briefxtant medicals units enters into sixteenth amendment to amended and restated credit agreement jul   briefxtant medical holdings effective june   units entered into fifteenth amendment to amended restated credit agreement jul   brieforbimed advisors reports  pct stake in xtant medical holdings‍​ may   briefxtant medical reschedules annual meeting may   briefxtant medical enters licensing agreement for sites medicals osteosync ti technology may   » more xtnta news related topics stocksstock screenerhealthcareadvanced medical equipment  technology xtant medical holdings inc xtnt  product pipeline analysis  update updated  the business research store the business research store × latest market research reports search by topic featured publishers become a partner special offers contact us  xtant medical holdings inc xtnt  product pipeline analysis  update updated  single user price   single user price  xtant medical holdings inc xtnt  product pipeline analysis  update updated  site license price   site license price  xtant medical holdings inc xtnt  product pipeline analysis  update updated  enterprise license price   enterprise license price xtant medical holdings inc xtnt  product pipeline analysis  update updated  published by global data  may     in stocksummaryxtant medical holdings inc xtant medical formerly bacterin international holdings inc is a medical device company that develops regenerative medicine products and medical devices the company’s products include demin osteosponge osteosponge sc osteoselect dbm putty osteostx osteowrap orbitalwrap hd facet stabilization milled cervical spacers traditional allografts hmatrix adm hmatrix pr adm and sports medicine it utilizes sterile technology for manufacturing bacterin products the company offers its products for the treatment of degenerative traumatic and deformity conditions for orthopedic and neurological applications it operates in louisiana maryland oregon illinois delaware california florida and new york xtant medical is headquartered in belgrade montana the usthis report is a source for data analysis and actionable intelligence on the company’s portfolio of pipeline products the report provides key information about the company its major products and brands the report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantagescope the report reviews detailed company profile with information on business description key company facts major products and services key competitors key employees locations and subsidiaries and recent developments the report analyzes all pipeline products in development for the company xtant medical holdings inc the report provides pipeline analysis on all pipeline products of the company by equipment type by indication by development stage and by trial status the report covers detailed information on each pipeline product with information on pipeline territory stage of development device class regulatory path indications applications and estimated launch date the report provides detailed description of products in development technical specification and functions the report also covers ongoing clinical trials wherever applicable with information on trial name trial objective sponsor trial design  trial status and phase estimated start and end datereasons to buy develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape design and develop your product development marketing and sales strategies by understanding the competitor portfolio to formulate effective research  development strategies develop marketentry and market expansion strategies exploit inlicensing and outlicensing opportunities by identifying products most likely to ensure a robust return plan mergers and acquisitions effectively by identifying key players of the most promising pipeline  identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials stage and of development etc identify understand and capitalize the next highvalue products that your competitor would add in its portfolionote some sections may be missing if data is unavailable for the company  xtant medical holdings inc xtnt  product pipeline analysis  update updated  single user price   single user price  xtant medical holdings inc xtnt  product pipeline analysis  update updated  site license price   site license price  xtant medical holdings inc xtnt  product pipeline analysis  update updated  enterprise license price   enterprise license price introductionsummaryxtant medical holdings inc xtant medical formerly bacterin international holdings inc is a medical device company that develops regenerative medicine products and medical devices the company’s products include demin osteosponge osteosponge sc osteoselect dbm putty osteostx osteowrap orbitalwrap hd facet stabilization milled cervical spacers traditional allografts hmatrix adm hmatrix pr adm and sports medicine it utilizes sterile technology for manufacturing bacterin products the company offers its products for the treatment of degenerative traumatic and deformity conditions for orthopedic and neurological applications it operates in louisiana maryland oregon illinois delaware california florida and new york xtant medical is headquartered in belgrade montana the usthis report is a source for data analysis and actionable intelligence on the company’s portfolio of pipeline products the report provides key information about the company its major products and brands the report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantagescope the report reviews detailed company profile with information on business description key company facts major products and services key competitors key employees locations and subsidiaries and recent developments the report analyzes all pipeline products in development for the company xtant medical holdings inc the report provides pipeline analysis on all pipeline products of the company by equipment type by indication by development stage and by trial status the report covers detailed information on each pipeline product with information on pipeline territory stage of development device class regulatory path indications applications and estimated launch date the report provides detailed description of products in development technical specification and functions the report also covers ongoing clinical trials wherever applicable with information on trial name trial objective sponsor trial design  trial status and phase estimated start and end datereasons to buy develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape design and develop your product development marketing and sales strategies by understanding the competitor portfolio to formulate effective research  development strategies develop marketentry and market expansion strategies exploit inlicensing and outlicensing opportunities by identifying products most likely to ensure a robust return plan mergers and acquisitions effectively by identifying key players of the most promising pipeline  identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials stage and of development etc identify understand and capitalize the next highvalue products that your competitor would add in its portfolionote some sections may be missing if data is unavailable for the companytable of contentstable of contents table of contents list of tables list of figures xtant medical holdings inc company overview xtant medical holdings inc company snapshot xtant medical holdings inc pipeline products and ongoing clinical trials overview xtant medical holdings inc – pipeline analysis overview xtant medical holdings inc  key facts xtant medical holdings inc  major products and services xtant medical holdings inc pipeline products by development stage xtant medical holdings inc pipeline products overview antimicrobial coated generos cf antimicrobial coated generos cf product overview antimicrobial coated generos sb generator antimicrobial coated generos sb generator product overview disk augmentation system disk augmentation system product overview interbody fusion device interbody fusion device product overview lumbar dynamic posterior stabilization device lumbar dynamic posterior stabilization device product overview monetite granules based bone graft monetite granules based bone graft product overview next generation demineralized bone matrix allograft next generation demineralized bone matrix allograft product overview osteosponge sc  cartilage regeneration scaffold osteosponge sc  cartilage regeneration scaffold product overview xsert lumbar expandable interbody system xsert lumbar expandable interbody system product overview xtant d printer xtant d printer product overview xtant medical holdings inc  key competitors xtant medical holdings inc  key employees xtant medical holdings inc  locations and subsidiaries head office other locations  subsidiaries recent developments xtant medical holdings inc recent developments may   xtant medical reports first quarter revenue of  million  growth compared to the prior year period mar   xtant medical reports record fourth quarter revenue of  million  growth compared to prior year period feb   xtant medical announces appointment of carl oconnell to permanent ceo jan   xtant medical ceo dan goldberger announces resignation jan   xtnt announces preliminary fourth quarter and full year  revenue  adjusted ebitda nov   xtant medical receives fda clearance for the xsert lumbar expandable interbody system nov   xtant medical receives fda clearance to use allografts in the standalone irixc cervical cage nov   xtant medical announces first surgical cases of xspan laminoplasty fixation system nov   xtant medical holdings reports record third quarter  results nov   xtant medical receives approval of compliance plan from nyse mkt appendix methodology about globaldata contact us disclaimer list of tables in xtant medical holdings inc xtnt  product pipeline analysis  update updated list of tables xtant medical holdings inc pipeline products and ongoing clinical trials overview xtant medical holdings inc pipeline products by equipment type xtant medical holdings inc pipeline products by indication xtant medical holdings inc key facts xtant medical holdings inc major products and services xtant medical holdings inc number of pipeline products by development stage xtant medical holdings inc pipeline products summary by development stage antimicrobial coated generos cf  product status antimicrobial coated generos cf  product description antimicrobial coated generos sb generator  product status antimicrobial coated generos sb generator  product description disk augmentation system  product status disk augmentation system  product description interbody fusion device  product status interbody fusion device  product description lumbar dynamic posterior stabilization device  product status lumbar dynamic posterior stabilization device  product description monetite granules based bone graft  product status monetite granules based bone graft  product description next generation demineralized bone matrix allograft  product status next generation demineralized bone matrix allograft  product description osteosponge sc  cartilage regeneration scaffold  product status osteosponge sc  cartilage regeneration scaffold  product description xsert lumbar expandable interbody system  product status xsert lumbar expandable interbody system  product description xtant d printer  product status xtant d printer  product description xtant medical holdings inc key employees xtant medical holdings inc subsidiaries glossary list of figures charts and diagrams in xtant medical holdings inc xtnt  product pipeline analysis  update updated list of figures xtant medical holdings inc pipeline products by equipment type xtant medical holdings inc pipeline products by development stage additional detailspublisherglobal datapublisher informationreference  gdmepdnumber of pagesreport formatpdfrelated reportstitledate publishedprice frommore details xtant medical holdings inc xtnt  medical equipment  deals and alliances profilesummaryxtant medical holdings inc xtant medical formerly bacterin international holdings inc is jul  by global data usd  more info xtant medical holdings inc xtnt  pharmaceuticals  healthcare  deals and alliances profilesummaryxtant medical holdings inc xtant medical formerly bacterin international holdings inc is may  by global data usd  more info xtant medical holdings inc xtnt  financial and strategic swot analysis reviewsummaryxtant medical holdings inc xtant medical formerly bacterin international holdings inc is may  by global data usd  more info xtant medical holdings inc xtnt  medical equipment  deals and alliances profilesummaryxtant medical holdings inc xtant medical formerly bacterin international holdings inc is apr  by global data usd  more info xtant medical holdings inc xtnt  pharmaceuticals  healthcare  deals and alliances profilesummaryxtant medical holdings inc xtant medical formerly bacterin international holdings inc is feb  by global data usd  more info xtant medical holdings inc xtnt  medical equipment  deals and alliances profilesummaryxtant medical holdings inc xtant medical formerly bacterin international holdings inc is jan  by global data usd  more info xtant medical holdings inc xtnt  pharmaceuticals  healthcare  deals and alliances profilesummaryxtant medical holdings inc xtant medical formerly bacterin international holdings inc is dec  by global data usd  more info xtant medical holdings inc xtnt  medical equipment  deals and alliances profilesummaryxtant medical holdings inc xtant medical formerly bacterin international holdings inc is nov  by global data usd  more info xtant medical holdings inc company profile outlook business segments competitors goods and services swot and financial analysis“xtant medical holdings inc company profile” is a complete analysis of the company’s operations  nov  by o g analysis usd  more info this report is published by global data download free report summary pdfdownload our free report summary pdf it contains all the information on these web pages plus a proforma invoice request form should you need it to satisfy your companys internal order proceduresordering informationorders are processed immediately and you will be notified of the despatch date on confirmation of your orderaccepted card types buy now using our secure payment system we stock download our free report summary pdfdownload our free report summary pdf it contains all the information on these web pages plus a proforma invoice request form should you need it to satisfy your companys internal order procedures× best price pdf sample  xtant medical holdings inc xtnt  product pipeline analysis  update updated  single user price   single user price  xtant medical holdings inc xtnt  product pipeline analysis  update updated  site license price   site license price  xtant medical holdings inc xtnt  product pipeline analysis  update updated  enterprise license price   enterprise license price buy buy this report now  xtant medical holdings inc xtnt  product pipeline analysis  update updated  single user price   single user price  xtant medical holdings inc xtnt  product pipeline analysis  update updated  site license price   site license price  xtant medical holdings inc xtnt  product pipeline analysis  update updated  enterprise license price   enterprise license price × xtant medical holdings inc private company information  bloomberg july    am et healthcare equipment and supplies company overview of xtant medical holdings inc snapshot people company overview xtant medical holdings inc develops manufactures and markets regenerative medicine products and devices in the united states and internationally its biomaterial products include osteosponge that provides a natural scaffold for cellular ingrowth and exposes boneforming proteins to the healing environment osteosponge sc that fills bony defects in the subchondral region of joints osteoselect dbm putty for osteoinductive bone growth osteoselect plus for use as a bone void filler and bone graft substitute in the pelvis extremities and posterolateral spine and osteowrap that wraps around nonunion fractures to assist with fusion as well as could be used in conjunction with a hardware xtant medical holdings inc develops manufactures and markets regenerative medicine products and devices in the united states and internationally its biomaterial products include osteosponge that provides a natural scaffold for cellular ingrowth and exposes boneforming proteins to the healing environment osteosponge sc that fills bony defects in the subchondral region of joints osteoselect dbm putty for osteoinductive bone growth osteoselect plus for use as a bone void filler and bone graft substitute in the pelvis extremities and posterolateral spine and osteowrap that wraps around nonunion fractures to assist with fusion as well as could be used in conjunction with a hardware plate system the company also provides bacfast hd facet stabilization dowels osteostx for posterolateral spine surgery applications including scoliosis procedures hmatrix dermal scaffold an acellular matrix made from donated human dermal tissue that is used to replace a patient’s damaged tissue and demin a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone in addition it processes and sells sports allografts for anterior and posterior cruciate ligament repairs anterior cruciate ligament reconstruction and meniscal repair milled spinal allografts and traditional allografts for orthopedics neurology podiatry oralmaxillofacial genitourinary and plasticreconstructive applications further the company offers various products to treat a range of spinal and sacroiliac conditions including trauma degeneration deformity and tumor xtant medical holdings inc markets its products through direct sales consignment agents reseller distributors private label distributors and technology licensees the company was formerly known as bacterin international holdings inc and changed its name to xtant medical holdings inc in july  xtant medical holdings inc is headquartered in belgrade montana detailed description  cruiser lanebelgrade mt united states employees phone  wwwxtantmedicalcom key executives for xtant medical holdings inc mr carl d oconnell chief executive officer and director age  total annual compensation k mr john p gandolfo cpa chief financial officer secretary and treasurer age  total annual compensation k mr robert m di silvio consultant age  compensation as of fiscal year  xtant medical holdings inc key developments xtant medical holdings continues to evaluate its strategic alternatives may   xtant medical holdings inc amexxtnt announced on may   that its board of directors has rescheduled the companys annual meeting of stockholders originally scheduled for june   to a later date as the company continues to evaluate its strategic alternatives xtant medical holdings inc enters into amendment to senior credit facility with affiliates of orbimed advisors may   xtant medical holdings inc announced it has entered into an amendment to its senior credit facility with affiliates of orbimed advisors for a financing of up to  million with the proceeds being used to pay off its outstanding balance of approximately  million under its accounts receivable credit facility with silicon valley bank svb with the remainder for general working capital purposes additionally orbimed has deferred the interest originally due under the senior credit facility january   and march   to june   bacterin international inc enters into fourteenth amendment and restated credit agreement may   effective may   bacterin international inc as borrower the company xspine systems inc and xtant medical inc collectively as the guarantors ros acquisition offshore lp and orbimed royalty opportunities ii lp entered into the fourteenth amendment to amended and restated credit agreement the amendment which amended the existing amended and restated credit agreement the facility prior amendments to the facility deferred bacterins accrued interest payment date for the fiscal quarter ended on december   until may   the amendment further defers bacterins accrued interest payment date for the fiscal quarter ended on december   until june   while also deferring bacterins accrued interest payment date for the fiscal quarter ended on march   until june   the interest due on june   for the fiscal quarter ended on december   will be  plus interest accrued on such interest from january   until paid at a rate equal to  plus the higher of the libo rate as defined in the facility for the fiscal quarter ended on december   or  the interest due on june   for the fiscal quarter ended on march   will be  plus interest accrued on such interest from april   until paid at a rate equal to  plus the higher of the libo rate for the fiscal quarter ended on march   or  the amendment also allows for xspine to make addition term loans with ros and royalty opportunities in an aggregate amount of up to  the amount of each loan draw made by xspine will be subject to a the companys production of a thirteenweek cash flow forecast that is approved by ros and royalty opportunities similar private companies by industry company name region decimal inc united states  genesystems inc united states  imaging llc united states st century scientific inc united states x corporation united states recent private companies transactions typedate target no transactions available in the past  months request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup most searched private companies company name geographic region lawyers committee for civil rights under law united states nyc inc united states the advertising council inc united states bertelsmann ag europe rush university united states sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact xtant medical holdings inc please visit wwwxtantmedicalcom company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close xtnt key statistics  xtant medical holdings inc financial ratios  marketwatch bulletin investor alert expand keep open close expand keep open close expand keep open close expand keep open close expand keep open close xtant medical holdings inc nyse american xtnt go set alerts find a broker join td ameritrade market index overview profile news charts financials historical quotes analyst estimates options sec filings insiders marketstatecountryus xtant medical holdings inc after hours  quotes are delayed by  min jul    pm xtnt quoteszigmancomposite   change   volume volume  quotes are delayed by  min quoteszigmancomposite previous close     change   day low day high    week low  week high   company description xtant medical holdings inc operates as a holding company which supplies orthopedic and spine surgery products the company operates through its subsidiaries bacterin international inc and xspine systems inc bacterin international develops manufactures and markets biologics products to dom xtant medical holdings inc operates as a holding company which supplies orthopedic and spine surgery products the company operates through its subsidiaries bacterin international inc and xspine systems inc bacterin international develops manufactures and markets biologics products to domestic and international markets its products are bone graft which are used in promotion of skull healing following neurosurgery and subchondral bone repair in knee and other joint surgeries and custom surgical products used for allografts xspine systems is a manufacturer of implants and instruments for surgery of the spine and sacroiliac joint its products are used for the treatment of degenerative spine disorders the company is headquartered in belgrade mt valuation pe current  pe ratio with extraordinary items  price to sales ratio  enterprise value to ebitda  enterprise value to sales  total debt to enterprise value  efficiency revenueemployee  income per employee  receivables turnover  total asset turnover  liquidity current ratio  quick ratio  cash ratio  profitability gross margin  operating margin  pretax margin  net margin  return on assets  return on equity  return on total capital  return on invested capital  capital structure total debt to total capital  total debt to total assets  longterm debt to total capital  officers and executives name age officer since title mr carl d oconnell   president chief executive officer  director mr michael schmitz   chief operating officer mr john p gandolfo   chief financial officer dr gregory a juda   chief scientific officer mr david baker   chief restructuring officer insider actions – purchase – sale  – number of transactions  sponsored topics see a problem let us know founded in  bacterin international specializes in the field of biomaterials research development and commercialization it offers tissue constructs and bioactivecoated devices to the medical device manufacturers the company designs tests and licenses bioactive coatings for medical applications additionally it provides antiinfective coatings for medical devices to prevent microbial formation and reduce infection rates the company s proprietary bioactive coatings can be applied to medical products to release bioactive molecules and antimicrobial and other suitable drugs bacterin international develops novel coatings for products to be used in the presence of different body fluids its coatings contain heparin that can be used to prevent clotting on the surface of vascular catheters the company is located in belgrade mont legal help bing places for business bing places for business sign in using your microsoft account work account google account facebook account dont have an account create one xtant medical – helping people have better lives xtant medical go helping people have better lives xtant medical unites exceptional biologics with intuitive fixation design to inspire surgical solutions that advance regenerative medicine learn about us advancing solutions that can restore lives biologics our tissue processing facility includes stateoftheart equipment to design and manufacture a portfolio of proprietary biologic products for orthopedic and spine applications we are committed to the ideals of the donate life community view all biologics fixation we are a global developer and manufacturer of implants and surgical instruments who create solutions and techniques to advance modern spine treatments view all fixation news  updates view all news xtant medical to announce second quarter  results on august th  jul   xtant medical announces rescheduling of annual meeting may   xtant medical enters into licensing agreement for sites medical’s osteosync ti technology may   news – xtant medical xtant medical go news news xtant medical to announce second quarter  results on august th  july   syndicated belgrade mont july   globe newswire  xtant medical holdings inc nyse mktxtnt a leader in the development of regenerative medicine products and medical devices today announced that it will release its financial results for the second quarter ended june   after the close of the financial markets on wednesday august   an accompanying conference call will be conducted by carl oconnell chief executive officer and president and john gandolfo chief financial … read more xtant medical announces rescheduling of annual meeting may   syndicated belgrade mont may   globe newswire  xtant™ medical holdings inc nyse mktxtnt a leader in the development of regenerative medicine products and medical devices today announced that its board of directors has rescheduled the companys annual meeting of stockholders originally scheduled for june   to a later date as the company continues to evaluate its strategic alternatives the company will announce a new annual meeting date and record date when they are deter… read more xtant medical enters into licensing agreement for sites medical’s osteosync ti technology may   syndicated belgrade mont may   globe newswire  xtant medical holdings inc nyse mktxtnt a leader in the development manufacturing and marketing of orthopedic products for domestic and international markets today announced it has entered into a licensing agreement with sites medical llc for utilization of their proprietary osteosync™ ti technology a bestinclass porous titanium scaffold we are very excited to work with sites medical said carl oconnell ceo of xtant medical… read more xtant medical announces orbimed financing and engagement of aurora management partners may   syndicated belgrade mont may   globe newswire  xtant™ medical holdings inc nyse mktxtnt a leader in the development of regenerative medicine products and medical devices today announced it has entered into an amendment to its senior credit facility with affiliates of orbimed advisors “orbimed” for a financing of up to  million with the proceeds being used to pay off its outstanding balance of approximately  million under its accounts receivable credit facility with sili… read more xtant™ medical reports first quarter revenue of  million  growth compared to the prior year period may   syndicated first quarter  highlights consolidated total revenue increased  to  million compared to first quarter  revenue of  million consolidated gross profit increased  to  million compared to first quarter  gross profit of  million consolidated gross margins improved to  compared to  reported in the first quarter of  the company reported an ebitda gain of approximately  for the first quarter of  belgrade mont may   globe … read more xtant medical announces release of first quarter  results on may   may   syndicated belgrade mont may   globe newswire  xtant medical holdings inc nyse mktxtnt a leader in the development of regenerative medicine products and medical devices announced that it will release its financial results for the first quarter ended march st  at the close of the financial markets on tuesday may th an accompanying conference call will be conducted by carl oconnell chief executive officer and president and john gandolfo chief financial officer to revie… read more xtant medical recognized as montana ambassador business of the year april   belgrade mont april   globe newswire  xtant medical holdings inc nyse mktxtnt a leader in the development manufacturing and marketing of orthopedic products for domestic and international markets today announced it has been named as the montana ambassador business of the year xtant medical was honored for making an outstanding contribution to the economic development in montana we are incredibly humbled to receive this recognition … read more xtant™ medical receives going concern opinion april   syndicated belgrade mont april   globe newswire  xtant™ medical holdings inc nyse mktxtnt a leader in the development of regenerative medicine products and medical devices today announced that as previously disclosed in its annual report on form k for the year ended december   which was filed on march   with the securities and exchange commission its audited financial statements contained a going concern qualification paragraph in the audit opinion from its inde… read more xtant™ medical reports record fourth quarter revenue of  million  growth compared to prior year period march   syndicated see footnote about the use of pro forma financial information fourth quarter  highlights consolidated total revenue increased  to a record  million compared to fourth quarter  revenue of  million consolidated gross profit increased  to  million compared to fourth quarter  gross profit of  million consolidated gross margins improved to  compared to  reported in the fourth quarter of  fullyear  highlights consolidated gross profit i… read more xtant medical to announce fourth quarter and full year  results on march th  march   syndicated belgrade mont march   globe newswire  xtant medical holdings inc nyse mktxtnt a leader in the development of regenerative medicine products and medical devices today announced that it will release its financial results for the fourth quarter and year ended december   after the close of the financial markets on thursday march   an accompanying conference call will be conducted by carl oconnell chief executive officer and president and john gandolfo chie… read more xtant medical announces appointment of carl o’connell to permanent ceo february   syndicated belgrade mont feb   globe newswire  xtant medical holdings inc nyse mktxtnt a leader in the development of regenerative medicine products and medical devices today announced the appointment of carl o’connell as the permanent ceo effective february th  mr oconnell previously served as president of xtant since october of  and was appointed as interim ceo on january st  prior to joining xtant medical mr oconnell most recently served as the vice p… read more xtant medical ceo dan goldberger announces resignation january   syndicated belgrade mont jan   globe newswire  xtant medical holdings inc nyse mktxtnt a leader in the development manufacturing and marketing of orthopedic products for domestic and international markets today announced that on january   dan goldberger resigned as chief executive officer and as a director of the company and its subsidiaries to pursue other interests current president carl o’connell will serve as interim ceo while the company’s board of directors cont… read more xtant medical – helping people have better lives xtant medical go helping people have better lives xtant medical unites exceptional biologics with intuitive fixation design to inspire surgical solutions that advance regenerative medicine learn about us advancing solutions that can restore lives biologics our tissue processing facility includes stateoftheart equipment to design and manufacture a portfolio of proprietary biologic products for orthopedic and spine applications we are committed to the ideals of the donate life community view all biologics fixation we are a global developer and manufacturer of implants and surgical instruments who create solutions and techniques to advance modern spine treatments view all fixation news  updates view all news xtant medical to announce second quarter  results on august th  jul   xtant medical announces rescheduling of annual meeting may   xtant medical enters into licensing agreement for sites medical’s osteosync ti technology may   xtant™ medical reports first quarter revenue of  million  growth compared to the prior year period nysextnt english français register sign in xtant™ medical reports first quarter revenue of  million  growth compared to the prior year period may    et  source xtant medical holdings inc first quarter  highlights consolidated total revenue increased  to  million compared to first quarter  revenue of  millionconsolidated gross profit increased  to  million compared to first quarter  gross profit of  millionconsolidated gross margins improved to  compared to  reported in the first quarter of the company reported an ebitda gain of approximately  for the first quarter of  belgrade mont may   globe newswire  xtant™ medical holdings inc nyse mktxtnt a leader in the development of regenerative medicine products and medical devices today reported its financial results for the quarter ended march st  the company reported first quarter  revenue of approximately  million and an ebitda gain of approximately  for the period revenue consolidated first quarter  revenue was approximately  million an increase of  compared to revenue of approximately  million for the same period of  the increase in revenue was primarily driven by the continuing increase the companys revenue from biologics product lines gross profit consolidated gross profit for the first quarter of  was  million or  of revenues compared to gross profit of  million or  of revenues for the first quarter of  the increase in gross margin was primarily due to product mix and the continued focus on improved operating efficiency sales and marketing expensesconsolidated first quarter  sales and marketing expenses increased to  million compared to sales and marketing expenses of  million during the same period in  for the quarter sales and marketing as a percentage of revenues decreased slightly to  compared to  in the first quarter of  general and administrative expensesin the first quarter of  consolidated general and administrative expenses increased to  million compared to general and administrative expenses of million for the same period last year as a percentage of revenues general and administrative expenses were  during the period compared to  for the same period of  net income  lossfirst quarter  consolidated net loss narrowed to  million compared to net loss of  million during the yearago period first quarter  consolidated loss per share was  compared to a loss per share of  in the first quarter of  ebitdathe company defines earnings before interest taxes depreciation and amortization ebitda as net incomeloss from operations before depreciation amortization impairment charges nonrecurring expenses and noncash stockbased compensation consolidated ebitda for the first quarter of  was a gain of approximately  compared to a loss of  for the same period during  calculation of consolidated ebitda for the three months ended march   and  unaudited for the three months ended march    net losstax benefit provision  other income expense change in warrant derivative liabilityinterest expense  separation related expenses  acquisition and integration related expenses  noncash compensation  depreciation  amortization  ebitda gain loss       financial liquiditycash on hand as of march   was  million as compared to  million as of december   net working capital as of march   remained flat at  million as compared to  million as of december   outlook for full year as a result of the company’s ongoing review of its capital structure the company has made a decision to withdraw its previously provided  financial guidance the company will provide an update to shareholders once the review and related discussions have been finalized conference call to be held may  an accompanying listenonly conference call will be hosted by carl oconnell chief executive officer and john gandolfo chief financial officer to discuss the results the call will be held at  am et on may   please refer to the information below for conference call dialin information and webcast registration conference date may    am etconference dialin international dialin conference call name xtant medicals first quarter  results callwebcast registration click here following the live call a replay will be available on the companys website wwwxtantmedicalcom under investor info about xtant™ medical holdings incxtant medical holdings inc nyse mktxtnt develops manufactures and markets classleading regenerative medicine products and medical devices for domestic and international markets xtant products serve the specialized needs of orthopedic and neurological surgeons including orthobiologics for the promotion of bone healing implants and instrumentation for the treatment of spinal disease tissue grafts for the treatment of orthopedic disorders and biologics to promote healing following cranial and foot and ankle surgeries with core competencies in both biologic and nonbiologic surgical technologies xtant can leverage its resources to successfully compete in global neurological and orthopedic surgery markets for further information please visit wwwxtantmedicalcom important cautions regarding forwardlooking statementsthis press release contains certain disclosures that may be deemed forwardlooking statements within the meaning of the private securities litigation reform act of  that are subject to significant risks and uncertainties forwardlooking statements include statements that are predictive in nature that depend upon or refer to future events or conditions or that include words such as continue efforts expects anticipates intends plans believes estimates projects forecasts strategy will goal target prospects potential optimistic confident likely probable or similar expressions or the negative thereof statements of historical fact also may be deemed to be forwardlooking statements we caution that these statements by their nature involve risks and uncertainties and actual results may differ materially depending on a variety of important factors including among others  the ability to comply with covenants in the company’s senior credit facility and to make deferred interest payments the ability to maintain sufficient liquidity to fund operations the ability to remain listed on the nyse mkt the ability to obtain financing on reasonable terms the ability to increase revenue the ability to continue as a going concern the ability to maintain sufficient liquidity to fund operations the ability to achieve expected results the ability to remain competitive government regulations the ability to innovate and develop new products the ability to obtain donor cadavers for products the ability to engage and retain qualified technical personnel and members of the company’s management team the availability of company facilities government and thirdparty coverage and reimbursement for company products the ability to obtain regulatory approvals the ability to successfully integrate recent and future business combinations or acquisitions the ability to use net operating loss carryforwards to offset future taxable income the ability to deduct all or a portion of the interest payments on the notes for us federal income tax purposes the ability to service company debt product liability claims and other litigation to which we may be subjected product recalls and defects timing and results of clinical studies the ability to obtain and protect company intellectual property and proprietary rights infringement and ownership of intellectual property the ability to remain accredited with the american association of tissue banks influence by company management the ability to pay dividends and the ability to issue preferred stock and other factors additional risk factors are listed in the companys annual report on form k and quarterly reports on form q under the heading risk factors the company undertakes no obligation to release publicly any revisions to any forwardlooking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events except as required by law contact cg capital investorrelationscgcapital cgcapital xtant medical holdings incconsolidated statement of operations for the three months ended march   and unaudited            for the three months ended mar           of    of  amount revenue amount revenueorthopedic product sales        other          total revenue                     cost of sales                     gross profit                     operating expenses          general and administrative          sales and marketing          research and development          depreciation and amortization          acquisition and integration related expenses          separation related expenses          noncash consulting          total operating expenses                     net gain loss from operations                   other income expense          interest expense        change in warrant derivative liability          other income expense                    total other income expense                   net gain loss from operations before benefit provision for income taxes                   benefit provision for income taxes          current          deferred                     net income loss                 net income loss per share         basic        dilutive                  shares used in the computation         basic            dilutive                     xtant medical holdings inccondensed consolidated statements of cash flowsunaudited   for the three months ended march    operating activities      net loss  adjustments to reconcile net loss to net cash used in operating activities      depreciation and amortization      noncash interest      noncash consulting expensestock option expense      provision for losses on accounts receivable and inventory     change in derivative warrant liability    changes in operating assets and liabilities      accounts receivable      inventories     prepaid and other assets    accounts payable     accrued liabilities    net cash used in operating activities             investing activities      purchases of property and equipment and intangible assets    net cash used in investing activities    financing activities      payments on capital leases    net proceeds from the issuance of stock     net cash provided by financing activities           net change in cash and cash equivalents    cash and cash equivalents at beginning of period      cash and cash equivalents at end of period           xtant medical holdings inccondensed consolidated balance sheetsas of march   unaudited and as of december   audited       as of mar  as of dec    assets      current assets      cash and cash equivalents    trade accounts receivable net of allowance for doubtful accounts of  and  respectively      inventories net      prepaid and other current assets      total current assets             noncurrent inventories      property and equipment net      goodwill      intangible assets net      other assets      total assets           liabilities  stockholders deficit equity      current liabilities      accounts payable    accounts payable  related party      accrued liabilities      revolving line of credit      warrant derivative liability      current portion of capital lease obligations      total current liabilities      longterm liabilities      capital lease obligation less current portion      long term convertible debt less current portion      longterm debt less current portion      total liabilities             commitments and contingencies      stockholders equity      preferred stock      common stock      additional paidin capital      accumulated deficit    total stockholders’ equity deficit           total liabilities  stockholders’ equity             xtant medical holdings inccalculation of consolidated ebitda for the three ended march   and unaudited  for the three months ended march     net loss     tax benefit provision   other income expense  change in warrant derivative liability interest expense   separation related expenses   acquisition and integration related expenses   noncash compensation   depreciation  amortization   ebitda gain loss       related articles other press releases by xtant medical holdings inc xtant medical to announce second quarter  results on august th  july    xtant medical announces rescheduling of annual meeting may    xtant medical enters into licensing agreement for sites medical’s osteosync ti technology may    xtant medical announces orbimed financing and engagement of aurora management partners may    xtant medical sets annual meeting and record dates may     other news releases in calendar of events in the last  days  other news releases in earnings releases and operating results in the last  days profile xtant medical holdings inc   subscribe via rss  subscribe via atom  javascript belgrade montana united states media files xtant medical holdings inc logo logo url  copy the link below formats available original medium small newswire distribution network  management home newsroom rss feeds legal contact us about us globenewswire a nasdaq company is one of the worlds largest newswire distribution networks specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media investment community individual investors and the general public contact us corporate headquarters  rosecrans avenue suite  el segundo ca  phone   fax   european headquarters woolgate exchange  basinghall street london ecv ha uk phone     globenewswire inc all rights reserved xtant medical  investor overview  presentationsxtant medicalgopresentationshomeinvestorspresentationsclick here for webcastq  xtant medical holdings inc earnings conference call live at  am etq  xtant medical holdings inc earnings conference callthursday august    am et  webcast presentation helpclick here for webcastadd to calendar help javascript must be enabled to use this feature  click here to add this event to your calendardatetitle q  xtant medical holdings inc earnings presentation q  xtant medical holdings inc earnings presentation q  xtant medical holdings inc earnings conference call q  xtant medical holdings inc earnings presentation xtant medical holdings free writing prospectus  q  xtant medical holdings inc earnings conference call q  xtant medical holdings inc earnings presentation investor presentation q  xtant medical holdings inc earnings conference call q  xtant medical holdings inc earnings conference call q  xtant medical holdings inc earnings conference call q  xtant medical holdings inc earnings conference call q  bacterin international holdings inc earnings conference call q  bacterin international holdings inc earnings conference call bacterin international holdings inc at roth capital th annual conference q  bacterin international holdings inc earnings conference call bacterin international holdings inc at the singular research th annual best of the uncovereds conference q  bacterin international holdings inc earnings conference call q  bacterin international holdings inc earnings conference call q  bacterin international holdings inc earnings conference call bacterin international holdings inc at leerink swann global healthcare conference bacterin international holdings inc at noble financial equity conference q  bacterin international holdings inc earnings conference call bacterin international holdings inc investor call with ceo dan goldberger q  bacterin international holdings inc earnings conference callget help downloading or viewing the above file typesinvestor relationsinvestorspress releasesevent calendarsec filingsinvestor relations kitpresentationsstock informationemail alertsinformation requestcorporate governancemanagementboard of directors print page email page rss feeds ir contacts financial tear sheet